Rapid-Cycle Research Studies and Projects
PCORnet®, The National Patient-Centered Clinical Research Network
The Patient-Centered Outcomes Research Institute (PCORI) is committed to advancing the capacity of PCORnet®, The National Patient-Centered Clinical Research Network, to fulfill the need for stakeholder-prioritized rapid-cycle research studies and projects. The PCORI Board of Governors approved funding for rapid-cycle research studies and projects using PCORnet’s infrastructure to support stakeholder-prioritized rapid evidence generation. Research studies and projects that use PCORnet are funded to assess the feasibility of conducting future stakeholder-prioritized research and to complete small, rapid, observational research studies that address stakeholder-prioritized research questions.
Cancer: This rapid-cycle descriptive analysis project aims to learn about the patterns of use of molecular biomarkers (tumor or germline) and associated targeted cancer therapies for patients with new-onset solid tumors (all single primary invasive solid tumors) cared for in a variety of community and academic care settings.
Diabetes: This rapid-cycle descriptive analysis project is focused on describing and validating PCORnet data on the use of several major classes of glucose-lowering medications for type 2 diabetes.
Opioid Surveillance: This rapid-cycle descriptive analysis project aims to demonstrate PCORnet’s capacity to create a more robust Opioid Surveillance Data Set and address current gaps in timely access to clinical data necessary for surveillance, prevention, and intervention.
Patient-Reported Outcomes Measurement (PROM): This rapid-cycle descriptive analysis project provides an opportunity for demonstrating the utility and value of collecting patient-reported outcomes measures (PROMs) during routine care in a standardized format for use in research analyses conducted within PCORnet.
PCSK9 Inhibitors: The purpose of this rapid-cycle descriptive analysis project is to learn about the trends and prevalence of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a class of medication therapies used to lower LDL cholesterol, or bad cholesterol, and treat hyperlipidemia.
Hepatitis C: This 12-month rapid-cycle retrospective observational research study conducted by investigators using PCORnet infrastructure aims to evaluate whether patients with hepatitis C virus (HCV) who are prescribed newer direct-acting antiviral (DAA) medications experience higher rates of adverse events than HCV patients who are untreated.
Posted: January 5, 2018; Updated: May 30, 2019
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.